Worse HIV control at diagnosis doesn't mean worse lymphoma outcomes - Aidsmap
Worse HIV control at diagnosis doesn't mean worse lymphoma outcomes Aidsmap
Non-Hodgkin Lymphoma News
FDA Orphan Drug Status Awarded to EO2463 in Indolent Non-Hodgkin Lymphoma - Targeted Oncology
FDA Orphan Drug Status Awarded to EO2463 in Indolent Non-Hodgkin Lymphoma Targeted Oncology
Hematologists Highlight Top Data From ASCO 2026 - OncLive
Hematologists Highlight Top Data From ASCO 2026 OncLive
Non-Hodgkin Lymphoma Treatment Market Size, Forecast, 2034 - Fortune Business Insights
Non-Hodgkin Lymphoma Treatment Market Size, Forecast, 2034 Fortune Business Insights
Legend surges on early data for ‘in vivo’ lymphoma cell therapy - BioPharma Dive
Legend surges on early data for ‘in vivo’ lymphoma cell therapy BioPharma Dive
Study reveals promising new therapy for non-Hodgkin lymphoma - Medical Xpress
Study reveals promising new therapy for non-Hodgkin lymphoma Medical Xpress
Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL) - Yahoo Finance
Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL) Yahoo Finance
The Evolving Roles of MRD and Molecular Genotyping in Non-Hodgkin Lymphoma - CancerNetwork
The Evolving Roles of MRD and Molecular Genotyping in Non-Hodgkin Lymphoma CancerNetwork
EHA2026 | Top abstracts: What’s hot in lymphoma and CLL - Lymphoma Hub
EHA2026 | Top abstracts: What’s hot in lymphoma and CLL Lymphoma Hub
ADC Therapeutics slumps on cancer drug safety scare - pharmaphorum
ADC Therapeutics slumps on cancer drug safety scare pharmaphorum
Non-Hodgkin's Lymphoma Market Size to Hit USD 26.22 Billion by 2035 - Precedence Research
Non-Hodgkin's Lymphoma Market Size to Hit USD 26.22 Billion by 2035 Precedence Research
Non-Hodgkin lymphoma: cocaine use disorder signals higher inpatient mortality and infectious complications - Vera Health
Non-Hodgkin lymphoma: cocaine use disorder signals higher inpatient mortality and infectious complications Vera Health
Health Canada authorizes Lunsumio® (mosunetuzumab) for the treatment of relapsed or refractory follicular lymphoma after two or more systemic therapies - Newswire Canada
Health Canada authorizes Lunsumio® (mosunetuzumab) for the treatment of relapsed or refractory follicular lymphoma after two or more systemic therapies Newswire Canada
Legend soars on ‘best-in-class,’ ‘best-in-disease’ in vivo CAR T in early lymphoma study - BioSpace
Legend soars on ‘best-in-class,’ ‘best-in-disease’ in vivo CAR T in early lymphoma study BioSpace
Early lymphoma trial: one-time CAR-T saw all higher-dose patients respond - Stock Titan
Early lymphoma trial: one-time CAR-T saw all higher-dose patients respond Stock Titan
5-Year Follow-Up From AUGMENT Lenalidomide Plus Rituximab in Relapsed or Refractory Indolent Non-Hodgkin Lymphoma - The ASCO Post
5-Year Follow-Up From AUGMENT Lenalidomide Plus Rituximab in Relapsed or Refractory Indolent Non-Hodgkin Lymphoma The ASCO Post
Report: Counties that spray the most glyphosate have higher non-Hodgkin lymphoma rates - Iowa Capital Dispatch
Report: Counties that spray the most glyphosate have higher non-Hodgkin lymphoma rates Iowa Capital Dispatch
Non-Hodgkins Lymphoma Market Trends and Insights - Precedence Research
Non-Hodgkins Lymphoma Market Trends and Insights Precedence Research
Non-Hodgkin lymphoma: inpatient TLS is uncommon but predictable from high–tumor burden and early lab derangements - Vera Health
Non-Hodgkin lymphoma: inpatient TLS is uncommon but predictable from high–tumor burden and early lab derangements Vera Health
New long-term analysis suggests follicular lymphoma can be cured - Fred Hutchinson Cancer Center
New long-term analysis suggests follicular lymphoma can be cured Fred Hutchinson Cancer Center
First-in-Human Clinical Trial Evaluates Bispecific Antibody for Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma - Roswell Park Comprehensive Cancer Center
First-in-Human Clinical Trial Evaluates Bispecific Antibody for Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Roswell Park Comprehensive Cancer Center
Rethinking Dual Targeting, Durability After CAR-T in Non-Hodgkin Lymphoma - CancerNetwork
Rethinking Dual Targeting, Durability After CAR-T in Non-Hodgkin Lymphoma CancerNetwork
Roundup Non-Hodgkin’s Lymphoma Lawsuit [2026 Update] - robertkinglawfirm.com
Roundup Non-Hodgkin’s Lymphoma Lawsuit [2026 Update] robertkinglawfirm.com
Long-term follow-up demonstrates the curative potential of dual CD19/CD22 CAR-T-cell therapy alone or combined with autologous stem cell transplantation in TP53-altered relapsed/refractory B-cell non-Hodgkin lymphoma | Signal Transduction and Targete - Nature
Long-term follow-up demonstrates the curative potential of dual CD19/CD22 CAR-T-cell therapy alone or combined with autologous stem cell transplantation in TP53-altered relapsed/refractory B-cell non-Hodgkin lymphoma | Signal Transduction and Targete Nature
Enterome presents Phase 2 indolent non-Hodgkin lymphoma data at EHA showing EO2463 induces B cell target-specific CD8 T-cell expansion correlating with clinical outcomes - Yahoo Finance
Enterome presents Phase 2 indolent non-Hodgkin lymphoma data at EHA showing EO2463 induces B cell target-specific CD8 T-cell expansion correlating with clinical outcomes Yahoo Finance
First peek at Legend's in vivo CAR-T sends shares soaring - FirstWord Pharma
First peek at Legend's in vivo CAR-T sends shares soaring FirstWord Pharma
Primary extranodal marginal zone non-hodgkin lymphoma of the prostate: a case report - Frontiers
Primary extranodal marginal zone non-hodgkin lymphoma of the prostate: a case report Frontiers
Primary Pulmonary Non-Hodgkin Lymphoma: A Report of Two Cases and a Review of the Literature Emphasizing the Role of Radiotherapy - Cureus
Primary Pulmonary Non-Hodgkin Lymphoma: A Report of Two Cases and a Review of the Literature Emphasizing the Role of Radiotherapy Cureus
National Poetry Month: "Non-Hodgkin’s Lymphoma" - The Rumpus
National Poetry Month: "Non-Hodgkin’s Lymphoma" The Rumpus
Targeting CAR-T cell exhaustion in non-Hodgkin lymphoma: mechanistic insights and emerging clinical strategies - Frontiers
Targeting CAR-T cell exhaustion in non-Hodgkin lymphoma: mechanistic insights and emerging clinical strategies Frontiers
Understanding the origins of Hodgkin lymphoma cells could lead to better diagnostics - Medical Xpress
Understanding the origins of Hodgkin lymphoma cells could lead to better diagnostics Medical Xpress
Current treatment algorithm: diffuse large B cell lymphoma - Nature
Current treatment algorithm: diffuse large B cell lymphoma Nature
Cancer Drug Proves 100% Successful In Early Study; What's Next? - Investor's Business Daily
Cancer Drug Proves 100% Successful In Early Study; What's Next? Investor's Business Daily
CAR-NK Shows Long-Term Response in Waldenström Non-Hodgkin Lymphoma - Cure Today
CAR-NK Shows Long-Term Response in Waldenström Non-Hodgkin Lymphoma Cure Today
Low-grade B-cell non-Hodgkin lymphoma in the sternocleidomastoid muscle: a case report and review of literature - Frontiers
Low-grade B-cell non-Hodgkin lymphoma in the sternocleidomastoid muscle: a case report and review of literature Frontiers
New long-term analysis suggests follicular lymphoma can be cured - UW Homepage
New long-term analysis suggests follicular lymphoma can be cured UW Homepage
At 34, I Was Diagnosed With An Incurable Cancer. Here’s How I Beat The Odds After Being Given 3 Months To Live. - HuffPost
At 34, I Was Diagnosed With An Incurable Cancer. Here’s How I Beat The Odds After Being Given 3 Months To Live. HuffPost
Hepatitis virus-associated B cell non-Hodgkin’s lymphoma involves dysregulated epigenetic and RNA-mediated regulatory gene expression and altered snoRNA transcription - Nature
Hepatitis virus-associated B cell non-Hodgkin’s lymphoma involves dysregulated epigenetic and RNA-mediated regulatory gene expression and altered snoRNA transcription Nature
USMNT Legend Kasey Keller Opens Up About Non-Hodgkin Lymphoma Journey - Forbes
USMNT Legend Kasey Keller Opens Up About Non-Hodgkin Lymphoma Journey Forbes
Evolving therapeutic strategies in mantle cell lymphoma: advancements and future directions - Nature
Evolving therapeutic strategies in mantle cell lymphoma: advancements and future directions Nature